Gabapentin is NOT Recommended for Low Back Pain from Lumbar Spinal Stenosis
Gabapentin should not be used for your patient with lumbar spinal stenosis-related low back pain, even while undergoing physiotherapy. The most recent high-quality evidence demonstrates no superiority over placebo and an increased risk of adverse effects.
Evidence Against Gabapentin Use
Guideline Recommendations
The 2021 clinical practice guideline for lumbar spinal stenosis causing neurogenic claudication explicitly recommends against gabapentin use (very low-quality evidence) 1. This represents the most current expert consensus on this specific clinical scenario.
The 2017 American College of Physicians systematic review found no evidence supporting antiseizure medications (including gabapentin) for low back pain in general 2. Importantly, gabapentin is FDA-approved only for postherpetic neuralgia and epilepsy—not for spinal stenosis or mechanical low back pain 3.
Recent High-Quality Research
The most recent and highest-quality study (2025) directly addresses your question: a double-blind randomized placebo-controlled trial found that gabapentin (1800 mg/day) showed no significant differences from placebo in reducing neurogenic claudication pain, improving functional outcomes, or enhancing quality of life in lumbar spinal stenosis patients 4. Critically, gabapentin was associated with significantly higher adverse effects, particularly dizziness and sedation (p<0.001).
A 2023 meta-analysis of 392 patients similarly found no significant VAS score differences at 2,4, or 8 weeks, with only marginal benefit at 3 months but significantly higher adverse events (OR 5.88) 5.
Safety Concerns
Gabapentin carries substantial risks that outweigh any potential benefits:
- Cognitive impairment: A 2025 study found gabapentin prescription in chronic low back pain patients associated with increased dementia risk (RR: 1.29) and mild cognitive impairment (RR: 1.85), with risk escalating with prescription frequency 6
- Sedation and dizziness: FDA labeling warns of significant driving impairment, somnolence (19% vs 9% placebo), and dizziness (17% vs 7% placebo) 3
- Drug interactions: Synergistic CNS depression when combined with other sedatives 3
What to Do Instead
The 2021 guideline recommends multimodal nonpharmacological care as first-line treatment 1:
- Continue physiotherapy (already being done—this is appropriate)
- Add education and lifestyle modifications
- Consider manual therapy
- Implement behavioral change techniques with home exercise programs
If pharmacological intervention becomes necessary, the guideline suggests considering serotonin-norepinephrine reuptake inhibitors or tricyclic antidepressants (very low-quality evidence) rather than gabapentinoids 1.
Common Pitfall
Despite gabapentin being prescribed to 11-14% of isolated low back pain patients 7, this represents off-label use driven by non-clinical factors (patient sex, geography, insurance type) rather than evidence-based practice. The 2025 data showing 14.2% prescription rates for isolated low back pain demonstrates widespread inappropriate use 7.
Bottom line: Gabapentin offers no proven benefit for lumbar spinal stenosis pain beyond placebo, carries significant adverse effects including cognitive impairment and sedation, and contradicts current clinical practice guidelines. Your patient should continue physiotherapy without adding gabapentin.